Methods to Expand the Eligible Patient Population for HER2-Directed Targeted Therapies

摘要

The present disclosure provides improved methods for identifying breast cancer patients that receive an increased benefit from the addition of a HER2-targeted therapy, for example adjuvant trastuzumab, to chemotherapy.